Secondary endpoints: details revised at 3 of 6 entries
MinorTrial sites expanded: 16 → 25 locationsv10
MinorStudy sites: 15 to 16v9
MinorStudy sites: 14 to 15v8
MinorTrial sites expanded: 10 → 14 locationsv7
MinorTrial sites expanded: 7 → 10 locationsv6
MinorStudy sites: 5 to 7v5
MinorRe-verified, no change to tracked fieldsv4
MinorTrial sites expanded: 1 → 5 locations
Secondary endpoints: details revised at 4 of 6 entries
Primary endpoint revised
v3
NotableTrial status: Not Yet Recruiting to Recruiting
Start date changed from estimate of Mar 2026 to Apr 3, 2026
Site details revised
v2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main goal of the study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have favorable effects. In this study, 2 different doses will be tested, and long-term treatment effects will be investigated.
MH002 is a live biotherapeutic product (LBP). This is a biological medicine containing live bacteria used to restore the normal function of a gut that is damaged by ulcerative colitis (UC). Ulcerative colitis is a bowel disease that causes inflammation and sores in the gut.